abstract |
The present invention provides oligonucleotide analogs comprising modified subunit linkages and / or modified 3 ' and / or 5 ' -terminal groups. The described compounds are useful in the treatment of diseases where inhibition of protein expression or amelioration of abnormal mRNA spleen products provides a beneficial therapeutic effect. |